STAT3 deficiency prevents hepatocarcinogenesis and promotes biliary proliferation in thioacetamide-induced liver injury

Mitsuhiko Abe(Kurume University), Takuji Torimura(Omuta hospital), Atsutaka Masuda(Kurume University), Jun Akiba(Kurume University), Akihiko Yoshimura(Keio University), Yu Ikezono(Kurume University), Toru Nakamura(Hokkaido University), Hideki Iwamoto(Kurume University), Toshimitsu Tanaka(Kurume University), Takahiko Sakaue(Kurume University), Hironori Koga(Kurume University), Takafumi Yoshida(Kurume University), Michio Sata(Kurume University), Fumitaka Wada(Kurume University)
World Journal of Gastroenterology
September 28, 2017
10.3748/wjg.v23.i37.6833
Cited by 18

Related Papers

A novel cytokine‐inducible gene CIS encodes an SH2‐containing protein that binds to tyrosine‐phosphorylated interleukin 3 and erythropoietin receptors.
|The EMBO Journal|1995|758
Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
|Gut|2019|732
Therapeutic effects of restricted diet and exercise in obese patients with fatty liver
|Journal of Hepatology|1997|614
Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH‐HCC guidelines) 2019 update
|Hepatology Research|2019|539
Hepatitis C Virus Down-Regulates Insulin Receptor Substrates 1 and 2 through Up-Regulation of Suppressor of Cytokine Signaling 3
|American Journal Of Pathology|2004|536